Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

Some of these markers had a proven better sensitivity and specificity for cancer detection than urine cytology ... common genitourinary malignancy after prostate cancer. It is the fourth most ...

Most tonsil cancers are a type called squamous cell carcinoma. A small number of tonsil cancers are lymphomas. The information in this section is about squamous cell carcinoma. The treatment for ...

Prostate cancer is a type of malignancy that arises in the prostate gland. Prostate cancer tends to develop in older men, aged 50 and over. In many cases prostate cancer develops slowly, although ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says ...